Key terms
About AVIR
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AVIR news
Apr 29
7:00am ET
Atea Pharmaceuticals announces presentation on safety profile of bemnifosbuvir
Mar 27
7:06am ET
Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
Mar 01
1:07am ET
Atea Pharmaceuticals: Balancing Promising Prospects with Clinical and Regulatory Risks
Feb 28
4:39pm ET
Atea Pharmaceuticals reports Q4 EPS (47c), consensus (51c)
No recent press releases are available for AVIR
AVIR Financials
Key terms
Ad Feedback
AVIR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AVIR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range